Biagio Ricciuti: Stephen Liu on the evolving treatment landscape for SCLC

Biagio Ricciuti shared a post on X:

“Comprehensive overview of the evolving treatment landscape for SCLC by Stephen Liu.

DLL3 T cell engagers can produce very durable responses (though ORR is relatively low). Several ADCs are also being developed with encouraging efficacy data.”

Source: Biagio Ricciuti/X

More posts featuring Biagio Ricciuti and Stephen Liu.

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.